{"id":"NCT01596621","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","briefTitle":"A Study of Bendamustine in the Treatment of Chinese Participants With Indolent Non-Hodgkin Lymphoma Refractory to Rituximab Treatment","officialTitle":"An Open-Label Study to Evaluate Bendamustine Hydrochloride in the Treatment of Chinese Patients With Indolent Non-Hodgkin Lymphoma (NHL) Refractory to Rituximab Treatment","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-08-06","primaryCompletion":"2015-06-18","completion":"2017-04-24","firstPosted":"2012-05-11","resultsPosted":"2023-05-26","lastUpdate":"2023-05-26"},"enrollment":102,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Non-Hodgkin Lymphoma"],"interventions":[{"type":"DRUG","name":"Bendamustine hydrochloride","otherNames":["TreandaÂ®"]}],"arms":[{"label":"Bendamustine","type":"EXPERIMENTAL"}],"summary":"The primary objective of the study is to determine the overall response rate (ORR), which includes complete response (CR) and partial response (PR), to bendamustine treatment in participants with indolent non-Hodgkin lymphoma (NHL) that has progressed after rituximab or a rituximab-containing therapy.","primaryOutcome":{"measure":"Overall Response Rate (ORR) (Assessed by Independent Review Committee [IRC])","timeFrame":"From the date of the first administration of bendamustine to the first documentation of disease progression/relapse, new anticancer therapy, or death (regardless of cause), whichever occurred first (up to 2.5 Years)","effectByArm":[{"arm":"Bendamustine","deltaMin":73,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":12,"exclusionCount":13},"locations":{"siteCount":27,"countries":["China"]},"refs":{"pmids":["33967195"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":30,"n":102},"commonTop":["White blood cell count decreased","Neutropenia","Neutrophil count decreased","Leukopenia","Nausea"]}}